A Phase 2 interventional study of 608 and 608 in Axial Spondyloarthritis, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China — 6 open to participants now, 6 under way, 3 of them phase 3. Non-Radiographic Axial Spondyloarthritis · China.
Among the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 6th registered.
33 studies on the registry are indexed under Non-Radiographic Axial Spondyloarthritis; 12 are open to participants now.
Browse Non-Radiographic Axial Spondyloarthritis studies →6 of the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China are open now. Recruiting first, the newest first:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Chinese PLA General Hospital · Sites in China
Ages 18–65
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18+
Lingli Dong · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 5 Non-Radiographic Axial Spondyloarthritis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2019; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is below the median of 225 across 20 interventional studies indexed under Non-Radiographic Axial Spondyloarthritis.
Median enrollment 227 across the 10 interventional studies, 10,000 across the 1 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 9 most frequent:
This study is registered under Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., one of the names counted as 3SBio Inc.. Under that name alone:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.
3SBio Inc. has 2 studies filed under Non-Radiographic Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Non-Radiographic Axial Spondyloarthritis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07339566Phase 3Lingli DongEfficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect and safety of 608 in patients with nr-axSpA.
The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of 608 compared to placebo in patients with nr-axSpA.
33 studies on the registry are indexed under Non-Radiographic Axial Spondyloarthritis; 12 are open to participants now.
This study's planned enrollment of 180 is below the median of 225 across 20 interventional studies indexed under Non-Radiographic Axial Spondyloarthritis.
Browse Non-Radiographic Axial Spondyloarthritis studies →Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.
First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc..
Compared within Non-Radiographic Axial Spondyloarthritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Axial Spondyloarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
608 Dose A subcutaneous (SC) injection.
Drug: 608
608 Dose B subcutaneous (SC) injection.
Drug: 608
Placebo subcutaneous (SC) injection.
Drug: Placebo
608 subcutaneous (SC) injection.
608 subcutaneous (SC) injection.
Placebo subcutaneous (SC) injection.
The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response
Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the NRS signifies higher severity.
Time frame: From Baseline to Week 16
The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 20 Response
Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the NRS signifies higher severity.
Time frame: From Baseline to the Week 16
608 Concentration in Serum
The concentration of 608 in Serum.
Time frame: From Baseline to Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Sep 2025, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-Radiographic Axial Spondyloarthritis →
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. →